Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This study will combine three drugs: sorafenib, cyclophosphamide and topotecan.
Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this
combination. The investigators first need to find out the highest dose of sorafenib that can
be given safely together with cyclophosphamide and topotecan. This is the first study to test
giving these three drugs together and will help determine the highest dose of sorafenib that
can safely be given together with cyclophosphamide and topotecan to patients with
resistant/relapsed neuroblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
New Approaches to Neuroblastoma Therapy Consortium
Collaborators:
Children's Healthcare of Atlanta Children's Hospital Colorado Children's Hospital Los Angeles Children's Hospital Medical Center, Cincinnati Cook Children's Health Care System Dana-Farber Cancer Institute Lucile Packard Children's Hospital Memorial Sloan Kettering Cancer Center Seattle Children's Hospital The Hospital for Sick Children University of California, San Francisco University of Chicago University of Michigan